Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
HR7837119th CongressWALLET
Most Favored Patient Act of 2026
Sponsored By: Representative Meuser, Daniel [R-PA-9]
Introduced
Summary
Creates a Most Favored Nations drug-pricing test that ties certain U.S. drug prices to lower prices abroad. This bill would direct the Center for Medicare and Medicaid Innovation to run an MFN pricing model for specified Part B and Part D drugs and to add the model to program rules beginning in 2029.
Show full summary
- Manufacturers would have to offer the MFN price to MFN-eligible individuals and to pharmacies, mail-order dispensers, hospitals, clinicians, and other providers. They must also report pricing and sales data to the Secretary, and the Secretary can suspend MFN rules for a drug until April 1, 2029 if a covered agreement is likely.
- People enrolled in Medicaid, Medicare Part D, or receiving Part B drugs would be eligible to receive covered drugs at the MFN price when dispensed or administered. Pharmacies, hospitals, and clinicians are explicitly included as points of access.
- The MFN price is defined as the second-lowest applicable net price among eight reference countries and is adjusted for purchasing power. The test applies to drugs sold in two or more reference countries and would run for 5 years.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Most Favored Nation drug prices for Medicare, Medicaid
This bill would create a five-year Most Favored Nation (MFN) drug pricing test starting January 1, 2029. Manufacturers without a covered agreement would have to give MFN prices to eligible Medicare and Medicaid patients and to pharmacies and providers who dispense or administer the drugs. The MFN price would be the second-lowest average price paid in a group of reference countries, after rebates and discounts and adjusted for purchasing power. Manufacturers would also have to report pricing and sales data the Secretary needs to calculate MFN prices. The Secretary could pause MFN rules for a drug until April 1, 2029 if a manufacturer is likely to sign a covered agreement by December 31, 2028; covered agreements must include MFN access, reporting, and a commitment to increase U.S. manufacturing.
Sponsors & CoSponsors
Sponsor
Meuser, Daniel [R-PA-9]
PA • R
Cosponsors
There are no cosponsors for this bill.
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov